MyoKardia, Inc. (MYOK) financial statements (2021 and earlier)

Company profile

Business Address 333 ALLERTON AVENUE
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments416417558559315379399
Cash and cash equivalents101235444466246335347
Short-term investments31518211593694452
Restricted cash and investments000    
Other undisclosed current assets7744553
Total current assets:424425563563319384401
Noncurrent Assets
Operating lease, right-of-use asset01  
Property, plant and equipment16756555
Long-term investments and receivables14634470803328
Long-term investments14634470803328
Restricted cash and investments222222 
Other noncurrent assets      0
Other undisclosed noncurrent assets012300 
Total noncurrent assets:32745380884033
TOTAL ASSETS:456499616643407424434
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities48432826242116
Accounts payable6735323
Accrued liabilities41372520211914
Debt01     
Contract with customer, liability 1222
Other undisclosed current liabilities  4613119
Total current liabilities:48443231374547
Noncurrent Liabilities
Liabilities, other than long-term debt22 0000
Other liabilities22 0000
Total noncurrent liabilities:22 0000
Total liabilities:50463231374547
Stockholders' equity
Stockholders' equity attributable to parent406452584612371379387
Common stock0000000
Additional paid in capital884872862852573566558
Accumulated other comprehensive income (loss)1000(0)(0)(0)
Accumulated deficit(479)(420)(278)(240)(203)(187)(171)
Total stockholders' equity:406452584612371379387
TOTAL LIABILITIES AND EQUITY:456499616643407424434

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:    1297
Operating expenses(61)(145)(42)(40)(30)(27)(26)
Operating loss:(61)(145)(42)(40)(18)(18)(19)
Loss from continuing operations before equity method investments, income taxes:(61)(145)(42)(40)(18)(18)(19)
Other undisclosed income (loss) from continuing operations before income taxes(9)33    
Loss from continuing operations before income taxes:(70)(142)(38)(40)(18)(18)(19)
Income tax expense (benefit) (0)0    
Other undisclosed loss from continuing operations(0)      
Loss before gain (loss) on sale of properties:(70)(142)(38)(40)(18)(18)(19)
Other undisclosed net income12  22  
Net loss:(59)(142)(38)(37)(16)(18)(19)
Other undisclosed net income attributable to parent     21
Net loss available to common stockholders, diluted:(59)(142)(38)(37)(16)(16)(18)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(59)(142)(38)(37)(16)(18)(19)
Other comprehensive income (loss)0(0)00000
Comprehensive loss:(59)(142)(38)(37)(16)(18)(19)
Other undisclosed comprehensive income, net of tax, attributable to parent     21
Comprehensive loss, net of tax, attributable to parent:(59)(142)(38)(37)(16)(16)(18)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: